Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate’s Epidemiology’s coverage of GIST comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of GIST for each country, as…

Endometrial cancer is the sixth most common cancer in women worldwide. While the majority of patients present with early stage disease at diagnosis, efficacious therapeutic options for advanced or…

DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of cervical…

DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of cervical…

DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of cervical…

DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of cervical…

DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of cervical…

The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has resulted in a highly segmented space dominated by…

The high number of premium-priced non-small-cell lung cancer (NSCLC) therapies and the large number of NSCLC patients have resulted in a significant financial burden for payers. Costs are set to…